Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers (Q35583968)

9 August 2017

Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers (English)

1 reference

9 August 2017

Jacqueline Lehmann-Che

1

Jacqueline Lehmann-Che

0 references

Hugues de Thé

15

Hugues de Thé

0 references

Fabrice André

2

Fabrice André

0 references

Philippe Bertheau

10

Philippe Bertheau

1 reference

9 August 2017

7

Marc Espié

1 reference

9 August 2017

Louis-François Plassa

8

Louis-François Plassa

1 reference

9 August 2017

Christine Desmedt

3

1 reference

9 August 2017

Chafika Mazouni

4

1 reference

9 August 2017

Sylvie Giacchetti

5

1 reference

9 August 2017

Elisabeth Turpin

6

1 reference

9 August 2017

Michel Marty

9

1 reference

9 August 2017

Christos Sotiriou

11

1 reference

9 August 2017

Martine Piccart

12

1 reference

9 August 2017

W Fraser Symmans

13

1 reference

9 August 2017

Lajos Pusztai

14

1 reference

9 August 2017

12 March 2010

1 reference

9 August 2017

1 reference

9 August 2017

15

1 reference

9 August 2017

3

1 reference

9 August 2017

246-252

1 reference

High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors

9 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

HER-2 and topoisomerase II as predictors of response to chemotherapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

Identification of molecular apocrine breast tumours by microarray analysis.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

Family feud in chemosensitvity: p73 and mutant p53.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

Assessing TP53 status in human tumours to evaluate clinical outcome

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

In search of the tumour-suppressor functions of BRCA1 and BRCA2

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

Clinical implications of p53 mutations

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

27 July 2018

Cancer therapy and p53.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

P63 and P73: P53 mimics, menaces and more

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

A simple p53 functional assay for screening cell lines, blood, and tumors

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227956

Cancer biology: Can less be more for p53?

15 November 2018

1 reference

12 December 2020

p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial

1 reference

12 December 2020

Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25

1 reference

12 December 2020

Achilles' heel of cancer?

1 reference

12 December 2020

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

1 reference

12 December 2020

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

1 reference

12 December 2020

High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients

1 reference

12 December 2020

Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer

1 reference

12 December 2020

10.1634/THEONCOLOGIST.2009-0243

Identifiers

DOI

1 reference

9 August 2017

1 reference

9 August 2017

1 reference